|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ cutaneous lymphoproliferative disorders include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
|
16412208 |
2006 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ lymphoproliferative disorders of the skin: still an open question.
|
23149700 |
2012 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30-positive primary cutaneous lymphoproliferative disorders include several entities with differing clinical presentation but overlapping histological features, including lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (C-ALCL).
|
25131361 |
2015 |
|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD30 is a tumor necrosis factor receptor (TNFR) family member whose expression is associated with Hodgkin's disease, anaplastic large cell lymphomas, and other T and B lymphoproliferative disorders in humans.
|
28993768 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD30 Expression in Monomorphic Posttransplant Lymphoproliferative Disorder, Diffuse Large B-Cell Lymphoma Correlates With Greater Regulatory T-Cell Infiltration.
|
29126177 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ pseudolymphoma should be distinguished from malignant intravascular lymphoproliferative disorders.
|
29369392 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.
|
30630983 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL.
|
31705818 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A few recent case reports have demonstrated molecular evidence of T-cell clonality in TUGSE and CD30 immunoreactivity in the large atypical mononuclear cells, raising the possibility that a TUGSE subset may represent the oral counterpart of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
|
19846813 |
2009 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
|
27993440 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Additional studies will be needed to determine if t(2;5) status has any clinical significance for patients with CD30+ primary cutaneous lymphoproliferative disorders.
|
9638979 |
1998 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Anaplastic large cell cutaneous lymphomas are clinically and pathologically heterogeneous, CD30 + (Ki-1) lymphoproliferative disorders.
|
22565437 |
2012 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Another photoresponsive CTCL variant is lymphomatoid papulosis (LP), a CD30+ lymphoproliferative disease characterised by chronically recurring papules.
|
30325389 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases.
|
31355940 |
2020 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
At present, brentuximab vedotin, an antibody-drug conjugate composed of an anti-cluster of differentiation (CD)-30 antibody covalently linked to monomethyl auristatin E, is approved for the treatment of CD30+ lymphoproliferative disorders [lymphomatoid papulosis (LyP) and primary cutaneous-anaplastic large-cell lymphoma (pc-ALCL)] as well as transformed CD30+ mycosis fungoides (MF).
|
30430444 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Brentuximab vedotin is a very interesting new treatment for advanced tumor MF, Sezary syndrome, and primary cutaneous CD30+ lymphoproliferative disorders.
|
28400633 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CCR3 was expressed in 73% of cases of CD30+ lymphoproliferative disorders such as lymphomatoid papulosis and anaplastic large cell lymphoma.
|
31045236 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD8-positive, CD30-positive cutaneous lymphoproliferative disorders constitute a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma (ALCL), mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma and cutaneous peripheral T-cell lymphoma.
|
28497585 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
|
31640798 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment.
|
29719017 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Cutaneous CD30+ lymphoproliferative disorders constitute many cutaneous T-cell lymphomas and comprise lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL).Both have an excellent prognosis.
|
31466587 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
|
17083688 |
2006 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnosis of PC-ALCL relies strongly on clinicopathologic correlation given the potential morphologic, clinical and molecular overlap with the other cutaneous CD30+ LPD, lymphomatoid papulosis, and more aggressive hematolymphoid neoplasms.
|
28342276 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of CD30 in blastoid cutaneous infiltrates typically signifies a CD30 lymphoproliferative disorder, often requiring minimal immunohistochemical workup, if clinically consonant.
|
27893466 |
2017 |